Buy or sell guide

A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for DBV Technologies S.A..
Updated 2026-05-06
Wall Street currently rates DBVT buy with a 12-month price target of $46 (+130.5% upside). The sections below cover the bull case, key risks, and latest earnings context for DBVT.
Wall Street verdict
15 analysts currently cover DBVT. Below is their consensus rating, price target range, and implied upside.
According to 15 analysts, DBV Technologies S.A. (DBVT) is rated Buy with a consensus 12-month price target of $46 — representing 130% upside from today's price of $20. The bull case target is $51, the bear case is $40.
At $20.10, the consensus setup implies +130.5% versus the 12-month target.
Below, compare that institutional answer with the live analyst commentary on X for DBVT right now.
Live commentary on X
Real posts from high-reach stock analysts mentioning DBVT, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about DBVT in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy DBVT?
A structured look at the bull case, the risks, and the most recent earnings execution for DBVT before you decide whether to buy, hold, or sell.
DBVT beat estimates last quarter. Below are the key reasons analysts remain cautious and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates DBVT "Buy" — view the full analysis for the detailed bull case.
Wall Street rates DBVT buy, giving the bull case institutional backing from 15 analysts.
What can break the setup quickly
No AI-generated risk factors available for DBVT yet.
Watch whether new negative commentary on DBVT points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying DBVT stock.
DBVT looks attractive at current levels — Wall Street's consensus rating is "Buy" with a $46 price target (+130.5% upside from $20.10). This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +130.5% upside to the $46 target. In the past 30 days, 1 of 1 covering analysts raised their price targets — a bullish signal.
DBVT's consensus 12-month price target is $46, set by 15 Wall Street analysts. The bull case high is $51 and the bear case low is $40. From the current price of $20.10, this implies +130.5% upside.
DBVT appears undervalued — the $46 consensus target is +130.5% above today's $20.10. It trades at a forward P/E of 0.0x. Targets range from $40 (bear) to $51 (bull), reflecting different assumptions about growth and margins.
DBVT reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $46 target. Consider position sizing rather than going all-in pre-print.
Of 15 analysts covering DBV Technologies S.A. (DBVT): 0 Strong Buy, 10 Buy, 4 Hold, 1 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $46 (range $40–$51). Bullish analysts outnumber bearish by more than 2-to-1.
1 of the 15 analysts covering DBVT rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on DBV Technologies S.A..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.